Efficacy and Safety of Oral Tofacitinib in the Treatment of Vitiligo

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400092326

Enrollment

Unknown

Registered

2024-11-14

Start date

2024-12-30

Completion date

Unknown

Last updated

2024-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vitiligo

Interventions

Observation group:None

Eligibility

Sex/Gender

All

Age

12 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients diagnosed with vitiligo and received at least 3 months of oral tofacitinib treatment. Complete treatment and follow-up data are available.

Exclusion criteria

Exclusion criteria: Exclusion Criteria: Patients with incomplete data or less than 3 months of treatment. Patients with a history of other autoimmune diseases or who received other systemic immunosuppressive therapies.

Design outcomes

Primary

Measure	Time frame
Vitiligo area scoring index;	—

Countries

China

Contacts

Public ContactWenting Hu

Hangzhou Third People‘s Hospital

sendnote@126.com+86 159 6713 6252

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026